Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
J Clin Pharmacol
; 52(7): 1017-27, 2012 Jul.
Article
en En
| MEDLINE
| ID: mdl-21673137
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Glucemia
/
Somatostatina
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Año:
2012
Tipo del documento:
Article